Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials

BACKGROUND: Pirfenidone is an oral antifibrotic agent that has been shown to reduce the decline in lung function in patients with idiopathic pulmonary fibrosis (IPF). We performed an integrated analysis of safety data from five clinical trials evaluating pirfenidone in patients with IPF. METHODS: Al...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Open Respir Res
Main Authors: Lancaster, Lisa, Albera, Carlo, Bradford, Williamson Z, Costabel, Ulrich, du Bois, Roland M, Fagan, Elizabeth A, Fishman, Robert S, Glaspole, Ian, Glassberg, Marilyn K, King, Talmadge E, Lederer, David J, Lin, Zhengning, Nathan, Steven D, Pereira, Carlos A, Swigris, Jeffrey J, Valeyre, Dominique, Noble, Paul W
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2016
Assuntos:
Interstitial Lung Disease
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4716177/
https://ncbi.nlm.nih.gov/pubmed/26835133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjresp-2015-000105
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados